Treatment of Residual Myopic Refraction After 6 Months on Pseudophakic Patients Using Relex-Smile
Launched by EYE HOSPITAL PRISTINA KOSOVO · Dec 31, 2020
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
The residual myopic refraction after 6 month on pseudophakic patients using Relex-Smile surgery using VisuMax Femtosecond Laser.The residual myopic refractive power is between -0.75D till -5.50D.The optical zone(lenticule diameter) and cap diameter were 6.5 and 7.5 mm respectively.After dissection of both anterior and posterior planes, the lenticule was extracted through 120 degree superior 3.5mm incision and marked with a sterile marker(Viscot-Medster)
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • residual myopic refraction -0.75d till -5.50D
- • complain visual acuity regarding residual myopic refraction
- Exclusion Criteria:
- • active anterior segment pathologic features
- • previous corneal or anterior segment surgery
- • glaucoma
- • history of ocular inflammation
About Eye Hospital Pristina Kosovo
Eye Hospital Pristina, located in Kosovo, is a leading clinical research institution dedicated to advancing ophthalmic care through rigorous clinical trials. Committed to improving patient outcomes, the hospital specializes in innovative treatments and technologies in eye health. With a multidisciplinary team of experienced ophthalmologists and researchers, Eye Hospital Pristina actively participates in collaborative studies aimed at enhancing the understanding and management of various eye conditions. The institution prioritizes patient safety and ethical standards, ensuring the highest quality of care and adherence to international research protocols.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pristina, , Kosovo
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials